Bayer: Science For A Better Life

United States of America

Oncology Information for Grant Submissions

BHC Oncology Medical Affairs Department is interested in receiving and reviewing grant applications to support appropriate programs, which cover the following area of interest:

Therapeutic Areas/Disease States:

Non-Hodgkin Lymphoma (NHL)

Intended Audience: Hematologic Oncologists, Nurses, Pharmacists, Patients/Caregivers

Areas of interest based on referenced literature:

  • Treatment landscape in relapsed/refractory indolent NHL
    • Unmet need in Follicular lymphoma and management of high-risk patients (i.e. POD24)
  • Role of PI3K inhibition in treatment algorithms in relapsed/refractory indolent NHL
    • Role of PI3K and synergistic pathways in NHL (i.e. follicular lymphoma, marginal zone lymphoma, diffuse large B-cell lymphoma, T-cell lymphomas)
    • Approved PI3K inhibitors for relapsed/refractory NHL
  • Adverse event management and safety considerations of PI3K inhibitors based on patient factors and comorbidities
    • Identification of proper patient population

Proposal Requirements:

All submissions for CE/CME support must be consistent with the ACCME guidelines and contain supporting documents that should include:

  • Needs assessment
  • Educational design and rationale for selection (where applicable)
  • Learning objectives
  • Proposed faculty
  • Participant recruitment plan (where applicable)
  • Outcomes strategy/plan
  • Detailed budget (please use the template available on the website)

Provider Justification:

  • Copy of most recent accreditation letter and status
  • Sample of other program(s) in similar therapeutic area


Applications/proposals which are submitted and determined to be complete are reviewed monthly. Allow a minimum of 45 days from submission for response.

Acceptance of a BHC educational grant indicates that you will:

  • Reconcile grant funding within 60 days of completion of the educational program
  • Permit a Bayer Medical Affairs representative to audit live programs
  • Share activity data and outcomes metrics within 30 days of their availability


Management and treatment of indolent NHL

  1. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology: B-cell Lymphomas. Version 5.2019 – September 23, 2019 (link)
  2. Welaya, K, Casulo, C2. Follicular Lymphoma: Redefining Prognosis, Current Treatment Options, and Unmet Needs. Hematol Oncol Clin North Am. 2019 Aug;33(4):627-638. (link)
  3. Matasar, MJ et al. Follicular Lymphoma: Recent and Emerging Therapies, Treatment Strategies, and Remaining Unmet Needs. Oncologist. 2019 Jul 25. pii: theoncologist.2019-0138. (link)

    Role of PI3K inhibition

  4. Kevin Courtney, et al. The PI3K Pathway As Drug Target in Human Cancer. J Clin Onc, 2010: 28. 1075-1083. (link)
  5. Elias Jabbour, et al. Targeting the phosphoinositide 3-kinase pathway in hematologic malignancies. Haematologica 2014: 99, 7-18. (link)
  6. Faruk Ramadani, et al. The PI3K Isoforms p110α and p110δ are Essential for Pre-B Cell Receptor Signaling and B Cell Development. Science Signaling 2010: 3(134), pp. ra60. (link)
  7. Georgios Pongas, et al. PI3K signaling pathway in normal B cells and indolent B-cell malignancies. Seminars in Oncology 2016: 43, 647–654. (link)
  8. von Keudell, G, Moskowitz, AJ. The Role of PI3K Inhibition in Lymphoid Malignancies. Curr Hematol Malig Rep. 2019 Jul 29. (Epub ahead of print) (link)

    PI3K Inhibitors in NHL

  9. Ajay K. Gopal, et al. PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma. N Engl J Med 2014;370:1008-18. (link)
  10. Martin Dreyling, et al. Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma. Ann Oncol. 2017 Sep 1;28(9):2169-2178. (link)
  11. Georg Lenz, et al. Clinical outcomes and molecular characterization from a phase II study of copanlisib in patients with relapsed or refractory diffuse large B-cell lymphoma. Oral presentation at: 14th ICML; Hematological Oncology. 2017 June; 35 (S2): 68-69. (link)
  12. Martin Dreyling, et al. Efficacy of Copanlisib Monotherapy in Patients with Relapsed or Refractory Marginal Zone Lymphoma: Subset Analysis from the CHRONOS-1 Trial. Blood 2017; 130(1):4053. (ASH abstract). (link)
  13. Martin Dreyling, et al. Long-Term Efficacy and Safety from the Copanlisib CHRONOS-1 Study in Patients with Relapsed or Refractory Indolent B-Cell Lymphoma. Blood. 2018:1595 (ASH abstract) (link)
  14. Armando Santoro, et al. Outcomes for Patients with High-Risk Relapsed or Refractory Indolent B-Cell Lymphoma Treated with Copanlisib in the CHRONOS-1 Study. Blood. 2018:395 (ASH abstract) (link)
  15. Pier Luigi Zinzani, et al. Outcomes for Patients with Pre-Existing Diabetes or Hypertension Treated with Copanlisib from the CHRONOS-1 Study in Patients with Relapsed or Refractory Indolent B-Cell Lymphoma. Blood. 2018: 1613 (ASH abstract)(link)
  16. Ian Flinn, et al. DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients With Refractory Indolent Non-Hodgkin Lymphoma. J Clin Oncol. 2019 Apr 10;37(11):912-922. (link)
  17. Leppä, S et al. Long-term follow-up of patients with relapsed or refractory follicular lymphoma treated with copanlisib. J Clin Onc 37(15), 2019: 7553-7553 (link)
  18. Eltantawy, A et al. Copanlisib: An Intravenous Phosphatidylinositol 3-Kinase (PI3K) Inhibitor for the Treatment of Relapsed Follicular Lymphoma. Ann Pharmacother. 2019 Sep;53(9):954-958. (link)
  19. Morschhauser F et al. On-Target Pharmacodynamic activity of the PI3K inhibitor Copanlisib in paired biopsies from patients with malignant lymphoma and advanced solid tumors. Mol Cancer Ther. 2019. (link)

    Adverse Event Management for PI3K Inhibitors

  20. Naifa L. Busaidy,et al. Management of Metabolic Effects Associated With Anticancer Agents Targeting the PI3K-Akt-mTOR Pathway. J Clin Onc, 2012: 30, 2919-2928. (link)
  21. Steven E. Coutré, et al. Management of adverse events associated with idelalisib treatment: expert panel opinion. Leukemia & Lymphoma, 56:10, 2779-2786. (link)
  22. Bruce D. Cheson, et al. Optimal Management of Adverse Events From Copanlisib in the Treatment of Patients With Non-Hodgkin Lymphomas. Clinical Lymphoma, Myeloma and Leukemia 2019; 19 (3), 135-141 (link)